Hyloris up as FDA accepts new drug application to treat post-operative pain

Hyloris Pharmaceuticals SA

01/11/2021 09:35

** Shares in Hyloris Pharmaceuticals  HYL.BR  jump 6% after
the Belgian company announced the acceptance from U.S. Food and
Drug Administration (FDA) of the new drug application (NDA) for
its drug Maxigesic IV in the treatment of post-operative pain
 urn:newsml:reuters.com:*:nASN001TPY
    ** NDA acceptance for Maxigesic IV, a novel combination of
paracetamol and ibuprofene for infusion, is "an important
milestone in the U.S. drug approval process", KBC notes
    ** The broker says patent approval is likely and expects it
to occur by early 2022
    ** It estimates 123 million euros in U.S. peak sales for
Maxigesic, which translates to 9.8 million euros royalty for
Hyloris
    ** The stock is on top of Belgian blue-chip index Bel 20
 .BFX 
    ** Including today's rise, it has gained 71.6% year-to-date

 (Reporting by Federica Mileo)
 ((Federica.mileo@thomsonreuters.com))